11.24.25 -- Exploring The Market For Closed-Loop Cell Therapy Production

Uncover why leveraging strong scientific expertise and comprehensive testing techniques will be vital in expediting development and upholding the integrity of these life-saving treatments.

The manufacturing process for autologous therapies is complex and highly customized, requiring well-orchestrated transport, careful planning, and tight control of many discrete and manual processing steps.

Ensure a smooth and efficient technology transfer by following key strategies and avoiding common pitfalls to streamline your process and achieve consistent, error-free results.

For complex projects involving oral solid dosage (OSD) and sterile drug products, selecting the ideal CDMO can play a pivotal role in determining the success of a drug candidate.

This HEK293-derived, animal component-free suspension cell line forms the foundation of a scalable, robust platform process that accelerates AAV manufacturing.

Delve into the safety of tumor-infiltrating leukocytes (TIL) therapies, it's important to use cGMP-compliant feeder cells confirmed to be non-proliferative through competency testing.

Learn how genome engineering and iPSCs are being used to overcome the critical challenges of durability and host immune clearance in both clinical and preclinical settings for allogeneic cell therapies.

See the pivotal role of cell lines in viral vector manufacturing, a complex, multi-step process that has traditionally been both time-consuming and labor-intensive.

Managing timelines to IND is the top challenge in cell therapy, impacting funding, patent value, and patient access amid competitive, capital-constrained development environments.

Assimilate how the secrets behind successes in commercializing and producing commercial cell and gene therapies, including establishing standards of every day, manufacturing operational excellence.

Accelerate access to high-quality, cost-effective lentiviral vectors with our intensified TFDF-based manufacturing platform, delivering multi-fold yield improvements and scalable, space-efficient production.

Effective CGT development hinges on phase-appropriate manufacturing. Matching manufacturing rigor to the clinical phase ensures the right quality at the right time while reducing costs and accelerating timelines.

Watch to gain valuable insights into the characterization of cellular source material for the development and manufacture of cell and gene therapy-based products.